Biotricity Awarded Research Grant to Study Next Generation Heart Rate Variability for Preventative Medicine Applications

Biotricity (OTCQB:BTCY) was awarded a research grant from the National Research Council-Industrial Research Assistance Program (NRC-IRAP) of Canada. The prestigious grant enables Biotricity to conduct research around the use of heart rate variability (HRV) in various applications for preventative medicine.
According to the company news:

The research will be led by Biotricity’s principal investigator Dr. David Liepert, who is collaborating with the University of Calgary and the Rockyview General Hospital. The NRC-IRAP is Canada’s premier technology assistance program for small and medium-sized enterprises, and a cornerstone in Canada’s innovation system that is regarded world-wide as one of the best programs of its kind.

Dr. David Liepert, a University of Calgary professor and anesthesiologist at Rockyview General Hospital commented:

HRV has been a research tool rather than a clinical tool for decades, but has the ability to predict the onset of a number of life-threatening disease states including strokes, heart attacks, sleep apnea, sepsis, etc. However, it is not mobile. HRV data collection mandates that patients be connected to a monitor, which has precluded the development of most clinical utilities. The next generation technology that we are researching and developing in this study and others will address this issue, and my research will focus on taking this approach to the next level.

Click here to view the full press release.